SAN DIEGO – March 12, 2003 – Althea Technologies, Inc., a leader in gene expression analysis, announced today that it presented data illustrating that its quantitative, multiplex PCR technology, eXpress Profiling™, can successfully monitor the impact of compounds on the expression of selected genes for early toxicological screening in a high-throughput format.
+
Headlines
ALL NEWS
Althea Presents Multiplex PCR Data Related To Toxicogenomics
Althea’s Express Profiling Technology Used In High-Throughput Multiplexed Gene Expression Study
SAN DIEGO – February 11, 2003 – Althea Technologies, Inc., a leader in high- throughput, gene expression analysis, announced today that the results of a pioneering study using multiplexed gene expression in compound library screening were published in the December 2002 edition of the journal Molecular Cancer Therapeutics.
+
Althea Technologies, Inc. Offers Full Scope Custom Integration Study Assays For DNA Vaccines
San Diego — October 19, 2000 — Althea Technologies, Inc., announced today that they now offer a full scope custom Integration Study to test for genomic integration of plasmid DNA vaccine products in injected animal muscle tissues. Each study includes a complex protocol of procedures designed to separate high molecular weight DNA from low molecular weight plasmid-derived DNA with a custom designed very sensitive and specific quantitative real time PCR amplification assay.
+
